Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012

    Access Status
    Fulltext not available
    Authors
    McLeod, C.
    Morris, P.
    Snelling, Thomas
    Carapetis, J.
    Bowen, A.
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    McLeod, C. and Morris, P. and Snelling, T. and Carapetis, J. and Bowen, A. 2014. Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012. Rural and Remote Health. 14 (2).
    Source Title
    Rural and Remote Health
    ISSN
    1445-6354
    School
    School of Public Health
    URI
    http://hdl.handle.net/20.500.11937/55902
    Collection
    • Curtin Research Publications
    Abstract

    Introduction: Australian Indigenous children suffer a high burden of diarrhoeal disease. Nitazoxanide is an antimicrobial that has been shown to be effective against a broad range of enteropathogens. To date, its use has not been reported in the tropical Top End (northernmost part) of the Northern Territory, Australia. The objective was to describe the use of nitazoxanide at the Royal Darwin Hospital, Northern Territory, and to assess any association with the time to resolution of diarrhoea. Methods: Eligible children (=13 years) were identified from dispensary records as having been prescribed nitazoxanide during the audit period, 1 July 2007 to 31 March 2012. Patient demographics, symptoms, diarrheal aetiology, treatment details and clinical outcomes were obtained by chart review. Results: Twenty-eight children were treated with nitazoxanide, mostly for Cryptosporidium infection associated with prolonged diarrhoea. Dehydration was evident in 27 (96%) children on admission, and 11 (41%) were underweight. Diarrhoeal duration prior to treatment was 11.5 days (6.5 days pre- and 5 days post-admission). For children =12 months, nitazoxanide was prescribed according to guidelines stipulated by the Centers for Disease Control and Prevention (CDC). Resolution of diarrhoea occurred a median of 2.4 days (IQR: 1.4-7.3) after starting treatment. An increase in weight for length at discharge was found for all children. Conclusions: Prompt resolution of diarrhoea without adverse outcomes suggests nitazoxanide may be an effective treatment for Cryptosporidium infection in this setting. Its role in the treatment of other causes of infectious diarrhoea needs further investigation. Randomised trials will further direct its use and determine optimal dosing regimens. © C McLeod, PS Morris, TL Snelling, JR Carapetis, AC Bowen, 2014.

    Related items

    Showing items related by title, author, creator and subject.

    • Malawi and Millennium Development Goal 4: A Countdown to 2015 country case study
      Kanyuka, M.; Ndawala, J.; Mleme, T.; Chisesa, L.; Makwemba, M.; Amouzou, A.; Borghi, J.; Daire, Judith; Ferrabee, R.; Hazel, E.; Heidkamp, R.; Hill, K.; Álvarez, M.; Mgalula, L.; Munthali, S.; Nambiar, B.; Nsona, H.; Park, L.; Walker, N.; Daelmans, B.; Bryce, J.; Colbourn, T. (2016)
      © 2016 World Health Organization. Background: Several years in advance of the 2015 endpoint for the Millennium Development Goals (MDGs), Malawi was already thought to be one of the few countries in sub-Saharan Africa ...
    • Adherence to the integrated management of childhood illness guidelines in Namibia, Kenya, Tanzania and Uganda: Evidence from the national service provision assessment surveys
      Krüger, C.; Heinzel-Gutenbrunner, M.; Ali, Mohammed (2017)
      © 2017 The Author(s). Background: Integrated Management of Childhood Illness (IMCI) is regarded as a standard public health approach to lowering child mortality in developing countries. However, little is known about how ...
    • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
      Martin, M.; Holmes, F.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.; Mansi, J.; Barrios, C.; Gnant, M.; Tomaševic, Z.; Denduluri, N.; Šeparovic, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S.; Jakobsen, E.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.; Armstrong, A.; Link, J.; Joy, A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, Arlene; ExteNET Study Group (2017)
      Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.